僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax （HY-137774）, an BCL inhibitor to form Mirzotamab clezutoclax （HY-P99741）, involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax （ABBV-155） is a targeted antibody drug conjugate （ADC）